US Broker Ratings

BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is capturing the attention of investors with its compelling growth potential in the biotechnology sector. As a key player in healthcare, BridgeBio is making significant..

ResMed Inc. (RMD) Stock Analysis: Exploring a 30% Potential Upside in the Healthcare Sector

ResMed Inc. (NYSE: RMD), a prominent player in the healthcare sector, is catching the eye of investors with its robust market capitalization of $29.05 billion and a compelling potential upside..

Bruker Corporation (BRKR) Stock Analysis: Navigating Challenges with Strategic Innovations

Bruker Corporation (NASDAQ: BRKR), a prominent player in the healthcare sector, specifically within the medical devices industry, has been at the forefront of technological advancements in scientific instruments and analytical..

BeOne Medicines Ltd. (ONC) Stock Analysis: A 47% Upside Potential in Biotech Innovation

BeOne Medicines Ltd. (ONC), a burgeoning name in the biotechnology sector, is drawing significant attention from investors with its robust pipeline of oncology treatments and a compelling potential upside of..

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Exploring a 31.66% Potential Upside

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands out in the biotechnology sector with its potent mix of innovation and financial resilience. As a leader in the healthcare industry, Regeneron has carved..

Repligen Corporation (RGEN) Stock Analysis: Exploring a 19.79% Potential Upside for Investors

Repligen Corporation (NASDAQ: RGEN), a prominent player in the healthcare sector, specializes in the development and commercialization of bioprocessing technologies and systems. With a market capitalization of $8.29 billion, Repligen..

RadNet, Inc. (RDNT) Stock Analysis: Exploring a 47.76% Potential Upside in Diagnostic Imaging

RadNet, Inc. (NASDAQ: RDNT), a prominent player in the healthcare sector, specifically in diagnostics and research, is capturing investor attention with a compelling potential upside of 47.76%. With a market..

Royalty Pharma (RPRX) Stock Analysis: Evaluating Its 5.37% Potential Upside and Strong Buy Ratings

Royalty Pharma plc (NASDAQ: RPRX) stands as a unique player in the biotechnology sector, operating primarily as a buyer of biopharmaceutical royalties while funding innovation in the industry. Headquartered in..

Nuvalent, Inc. (NUVL) Stock Analysis: Navigating Its $9.77B Market Cap with Promising Cancer Therapies

Nuvalent, Inc. (NUVL), a clinical-stage biopharmaceutical company, has been making waves in the healthcare sector with its innovative approach to developing therapies for cancer patients. With a market capitalization of..

ADMA Biologics Inc (ADMA) Stock Analysis: Exploring a 101% Upside Potential with Strong Buy Ratings

ADMA Biologics Inc (NASDAQ: ADMA), a key player in the biotechnology industry, is capturing investor attention with its impressive potential upside of 101.14%. Operating within the healthcare sector, ADMA focuses..

Bio-Techne Corp (TECH) Stock Analysis: Navigating a Tightrope with Potential and Caution

Bio-Techne Corp (NASDAQ: TECH) is a significant player in the biotechnology sector, operating at the crossroads of healthcare and technology. With a market capitalization of $11.06 billion, this Minneapolis-based company..

TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring Growth Potential Amidst Notable Revenue Surge

TG Therapeutics, Inc. (NASDAQ: TGTX), a prominent player in the biotechnology sector, has been capturing investor interest with its impressive market performance and innovative therapeutic solutions. With a market capitalization..

Charles River Laboratories (CRL) Stock Analysis: Navigating Growth with a $10.39 Billion Market Cap

Charles River Laboratories International, Inc. (NYSE: CRL), a key player in the healthcare sector specializing in diagnostics and research, is drawing attention with its impressive market cap of $10.39 billion...

Alkermes plc (ALKS) Stock Analysis: Navigating Growth Amidst a Potential -12.63% Downside

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector, has been attracting significant attention from investors with its robust lineup of pharmaceutical products targeting unmet medical needs. Despite..

Natera, Inc. (NTRA) Stock Analysis: A Leading Diagnostic Innovator with Robust Revenue Growth and Strong Buy Ratings

Investors with a keen eye on the healthcare sector may find Natera, Inc. (NASDAQ: NTRA) an intriguing opportunity. As a prominent player in the diagnostics and research industry, Natera is..

Zoetis Inc. (ZTS) Stock Analysis: Is a 62.96% Upside Worth the Investment?

For investors eyeing the healthcare sector, Zoetis Inc. (ZTS) presents a compelling opportunity with a significant potential upside of 62.96%, according to analyst ratings. With a market cap of $31.9..

West Pharmaceutical Services (WST) Stock Analysis: Strong Revenue Growth and Bullish Analyst Ratings Offer Promising Prospects

West Pharmaceutical Services, Inc. (NYSE: WST), a prominent player in the healthcare sector with a focus on medical instruments and supplies, has been capturing investor attention with its robust market..

Centene Corporation (CNC) Stock Analysis: Navigating the Healthcare Sector with a -5.93% Potential Downside

Centene Corporation (NYSE: CNC), a significant player in the healthcare plans industry, presents an intriguing case for investors navigating the dynamic healthcare sector. With a market capitalization of $32.46 billion,..

Guardant Health, Inc. (GH) Stock Analysis: Navigating High Growth in the Diagnostics Sector

Guardant Health, Inc. (NASDAQ: GH), a leader in precision oncology, is making waves in the healthcare sector with its cutting-edge diagnostic technologies. Headquartered in Palo Alto, California, this company is..

Lantheus Holdings, Inc. (LNTH) Stock Analysis: Strong Buy Ratings Amid Impressive ROE and Expanding Diagnostic Portfolio

Lantheus Holdings, Inc. (NASDAQ: LNTH) presents an intriguing proposition for investors focused on the healthcare sector, particularly in the specialty and generic drug manufacturing industry. With a market capitalization of..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds